# name
Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats.

# metadata.dc.description.abstract[].value
"Ivermectin is a widely used antiparasitic drug with known efficacy against several single-strain RNA viruses. Recent data shows significant
reduction of SARS-CoV-2 replication in vitro by ivermectin
                concentrations not achievable with safe doses orally. Inhaled
                therapy has been used with success for other antiparasitics. An
                ethanol-based ivermectin formulation was administered once to 14
                rats using a nebulizer capable of delivering particles with
                alveolar deposition. Rats were randomly assigned into three
                target dosing groups, lower dose (80-90\xC2\xA0mg/kg), higher
                dose (110-140\xC2\xA0mg/kg) or ethanol vehicle only. A
                toxicology profile including behavioral and weight monitoring,
                full blood count, biochemistry, necropsy and histological
                examination of the lungs was conducted. The pharmacokinetic
                profile of ivermectin in plasma and lungs was determined in all
                animals. There were no relevant changes in behavior or body
                weight. There was a delayed elevation in muscle enzymes
                compatible with rhabdomyolysis, that was also seen in the
                control group and has been attributed to the ethanol dose which
                was up to 11\xC2\xA0g/kg in some animals. There were no
                histological anomalies in the lungs of any rat. Male animals
                received a higher ivermectin dose adjusted by adipose weight and
                reached higher plasma concentrations than females in the same
                dosing group (mean C" - " 86.2\xC2\xA0ng/ml vs.
                26.2\xC2\xA0ng/ml in the lower dose group and 152\xC2\xA0ng/ml
                vs. 51.8\xC2\xA0ng/ml in the higher dose group). All subjects
                had detectable ivermectin concentrations in the lungs at seven
                days post intervention, up to 524.3\xC2\xA0ng/g for high-dose
                male and 27.3\xC2\xA0ng/g for low-dose females. nebulized
                ivermectin can reach pharmacodynamic concentrations in the lung
                tissue of rats, additional experiments are required to assess
                the safety of this formulation in larger animals."

# metadata.dc.source[].value
Articles publicats en revistes (ISGlobal)

# metadata.dc.title[].value
Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats.